Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Meldola – page 41

621 clinical trials in Meldola, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Meldola at a glance
621
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

621 trials in Meldola

Open in trial search

Breast cancer metastatic

Not recruiting

Study comparing giredestrant plus palbociclib versus letrozole plus palbociclib in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Giredestrant
  • Sponsor:F. Hoffmann-La Roche AG

Prostate cancer metastatic

Not recruiting

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Janssen Cilag International

Hormone receptor positive breast cancer+2

Not recruiting

Study of palbociclib with hormone therapy versus hormone therapy alone in patients with recurrent hormone receptor-positive/HER2-negative breast cancer after surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:ETOP IBCSG Partners Foundation

Follicular lymphoma

Not recruiting

Study of Zanubrutinib and Obinutuzumab for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Beigene Ltd.

Non-small cell lung cancer+1

Not recruiting

Study Comparing Pralsetinib and Standard Drug Combination for Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:F. Hoffmann-La Roche AG

Follicle centre lymphoma follicular grade I II - III refractory

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Ovarian cancer stage IV+1

Not recruiting

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Pfizer Inc.

Polycythaemia vera

Not recruiting

Study on the Effects of Rusfertide (PTG-300) for Patients with Polycythemia Vera

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rusfertide
  • Sponsor:Takeda Development Center Americas Inc.

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220
  • Sponsor:Alexion Pharmaceuticals Inc.

Warm autoimmune haemolytic anaemia+2

Not recruiting

Study on Povetacicept for Patients with Autoimmune Cytopenias (wAIHA, CAD, ITP)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Povetacicept
  • Sponsor:Alpine Immune Sciences Inc.

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Meldola

What the registry says about research in the country

01 Hematologic Malignancies

Innovative research focusing on blood cancers, including studies of novel therapeutic combinations for acute myeloid leukemia, multiple myeloma, and various lymphomas.

  • Advanced treatments for diffuse large B-cell lymphoma
  • Multiple myeloma therapies for transplant-ineligible patients
  • Novel approaches in myelodysplastic syndrome

Studies are evaluating targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Solid Tumors

Comprehensive research into advanced solid tumors, with particular emphasis on colorectal cancer, non-small cell lung cancer, and breast cancer.

  • Targeted therapies for metastatic colorectal cancer
  • Novel combinations for advanced NSCLC
  • Innovative approaches in metastatic breast cancer

Investigations focus on personalized treatment strategies and novel drug combinations.

03 Genitourinary Cancers

Groundbreaking studies in urological cancers, including research on prostate cancer, urothelial cancer, and renal cell carcinoma.

  • Advanced treatments for metastatic prostate cancer
  • Maintenance therapy in urothelial cancer
  • Immunotherapy approaches in renal cell carcinoma

Research aims to improve survival rates through innovative therapeutic strategies.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.